VCM
CSTL icon

Versant Capital Management’s Castle Biosciences CSTL Stock Holding History

Versant Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Sell
126
-120
-49% -$2.67K ﹤0.01% 2512
2026
Q1 		$6.04K Buy
246
+65
+36% +$2.13K ﹤0.01% 2329
2025
Q4 		$7.04K Hold
181
– – ﹤0.01% 2124
2025
Q3 		$4.12K Buy
181
+55
+44% +$1.12K ﹤0.01% 2279
2025
Q2 		$2.57K Buy
+126
New +$2.33K ﹤0.01% 2336

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management's CSTL Position: Q2 2026 in Review

Versant Capital Management reduced its Castle Biosciences (CSTL) stake by 49% in Q2 2026, selling an estimated $2.67K and leaving 126 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2512.

Versant Capital Management first reported a position in CSTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.04K in Q4 2025. 9 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Versant Capital Management held 126 shares of Castle Biosciences worth $3K as of Q2 2026.
  • Versant Capital Management sold 120 Castle Biosciences shares in Q2 2026, an estimated $2.67K.
  • Castle Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2512 holding.
  • Versant Capital Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Versant Capital Management's Castle Biosciences position peaked at $7.04K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.